Circulating Tumor Cells in Colorectal Cancer in the Era of Precision Medicine

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2021 Nov 21

PMID 34802071

Citations 14

Authors

Mingchao Hu

Zhili Wang

Zeen Wu

Pi Ding

Renjun Pei

Qiang Wang

Chungen Xing

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the main causes of cancer-related morbidity and mortality across the globe. Although serum biomarkers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA-199) have been prevalently used as biomarkers in various cancers, they are neither very sensitive nor highly specific. Repeated tissue biopsies at different times of the disease can be uncomfortable for cancer patients. Additionally, the existence of tumor heterogeneity and the results of local biopsy provide limited information about the overall tumor biology. Against this backdrop, it is necessary to look for reliable and noninvasive biomarkers of CRC. Circulating tumor cells (CTCs), which depart from a primary tumor, enter the bloodstream, and imitate metastasis, have a great potential for precision medicine in patients with CRC. Various efficient CTC isolation platforms have been developed to capture and identify CTCs. The count of CTCs, as well as their biological characteristics and genomic heterogeneity, can be used for the early diagnosis, prognosis, and prediction of treatment response in CRC. This study reviewed the existing CTC isolation techniques and their applications in the clinical diagnosis and treatment of CRC. The study also presented their limitations and provided future research directions.

Citing Articles

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.

Bahmaie N, Ozensoy Guler O, Simsek E J Liq Biopsy. 2025; 6:100169.

PMID: 40027303 PMC: 11863822. DOI: 10.1016/j.jlb.2024.100169.

The Potential of Metabolomics in Colorectal Cancer Prognosis.

Fu C, Liu X, Wang L, Hang D Metabolites. 2024; 14(12).

PMID: 39728489 PMC: 11677167. DOI: 10.3390/metabo14120708.

Expression levels and diagnostic value of serum GDNF, CEA and CA199 in patients with colorectal carcinoma.

Jue W, Lulu L, Yan Z, Gu S J Med Biochem. 2024; 43(2):250-256.

PMID: 38699694 PMC: 11062338. DOI: 10.5937/jomb0-44745.

Prognostic value of preoperative combined with postoperative systemic immune-inflammation index for disease-free survival after radical rectal cancer surgery: a retrospective cohort study.

Sun J, Yang R, Wu H, Li L, Gu Y Transl Cancer Res. 2024; 13(1):371-380.

PMID: 38410202 PMC: 10894347. DOI: 10.21037/tcr-23-1289.

New insights into the correlations between circulating tumor cells and target organ metastasis.

Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y Signal Transduct Target Ther. 2023; 8(1):465.

PMID: 38129401 PMC: 10739776. DOI: 10.1038/s41392-023-01725-9.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Primrose J, Perera R, Gray A, Rose P, Fuller A, Corkhill A . Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014; 311(3):263-70. DOI: 10.1001/jama.2013.285718. View

Carpelan-Holmstrom M, Louhimo J, Stenman U, Alfthan H, Haglund C . CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002; 22(4):2311-6. View

Khattak A . Liquid biopsies: advancing cancer research through drops of blood. Intern Med J. 2016; 46(3):376-7. DOI: 10.1111/imj.12996. View

Abouleila Y, Onidani K, Ali A, Shoji H, Kawai T, Lim C . Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells. Cancer Sci. 2018; 110(2):697-706. PMC: 6361580. DOI: 10.1111/cas.13915. View

Micevic G, Theodosakis N, Bosenberg M . Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics. 2017; 9:34. PMC: 5381063. DOI: 10.1186/s13148-017-0332-8. View

Zaretsky J, Garcia-Diaz A, Shin D, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S . Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016; 375(9):819-29. PMC: 5007206. DOI: 10.1056/NEJMoa1604958. View

Chen C, Lacke E, Stock C, Hoffmeister M, Brenner H . Colonoscopy and sigmoidoscopy use among older adults in different countries: A systematic review. Prev Med. 2017; 103:33-42. DOI: 10.1016/j.ypmed.2017.07.021. View

Zhang J, Cheng Z, Ma Y, He C, Lu Y, Zhao Y . Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis. Clin Colorectal Cancer. 2017; 16(4):252-263. DOI: 10.1016/j.clcc.2017.03.018. View

10.

Gazzaniga P, Raimondi C, Nicolazzo C, Carletti R, Di Gioia C, Gradilone A . The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells. Expert Rev Mol Diagn. 2015; 15(7):925-32. DOI: 10.1586/14737159.2015.1045491. View

11.

Liberko M, Kolostova K, Bobek V . Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol. 2013; 88(2):338-56. DOI: 10.1016/j.critrevonc.2013.05.002. View

12.

Joosse S, Gorges T, Pantel K . Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2014; 7(1):1-11. PMC: 4309663. DOI: 10.15252/emmm.201303698. View

13.

Torino F, Bonmassar E, Bonmassar L, De Vecchis L, Barnabei A, Zuppi C . Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev. 2013; 39(7):759-72. DOI: 10.1016/j.ctrv.2012.12.007. View

14.

Alix-Panabieres C, Pantel K . Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016; 6(5):479-91. DOI: 10.1158/2159-8290.CD-15-1483. View

15.

Danese E, Montagnana M, Lippi G . Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: which is ready for prime time?. Ann Transl Med. 2020; 7(21):610. PMC: 7011594. DOI: 10.21037/atm.2019.08.97. View

16.

Lim S, Becker T, Chua W, Ng W, de Souza P, Spring K . Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 2014; 67(10):848-53. DOI: 10.1136/jclinpath-2014-202499. View

17.

Markiewicz A, Nagel A, Szade J, Majewska H, Skokowski J, Seroczynska B . Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients. Transl Oncol. 2018; 11(3):722-731. PMC: 6056759. DOI: 10.1016/j.tranon.2018.03.006. View

18.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

19.

Ksiazkiewicz M, Markiewicz A, Zaczek A . Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012; 79(4):195-208. DOI: 10.1159/000337106. View

20.

Markiewicz A, Zaczek A . The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition. Pathobiology. 2017; 84(5):264-283. DOI: 10.1159/000477812. View